重组Anti-BCMA抗体[EPR22457-260] (ab253242)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR22457-260] to BCMA
- Suitable for: Flow Cyt, IP, ICC/IF, WB
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-BCMA抗体[EPR22457-260]
参阅全部 BCMA 一抗 -
描述
兔单克隆抗体[EPR22457-260] to BCMA -
宿主
Rabbit -
经测试应用
适用于: Flow Cyt, IP, ICC/IF, WBmore details
不适用于: IHC-P -
种属反应性
与反应: Human -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- WB: Recombinant his-tagged human BCMA protein (ab219697, aa1-54) ; U266B1 whole cell lysate. IP: U266B1 whole cell lysate. ICC/IF: U266B1 cells. Flow cyt: U266B1 cells.
-
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR22457-260 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Related Products
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab253242于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
Flow Cyt |
1/60.
|
|
IP |
1/30.
|
|
ICC/IF |
1/50.
|
|
WB |
1/1000. Detects a band of approximately 23, 19 kDa (predicted molecular weight: 20, 14 kDa).
|
说明 |
---|
Flow Cyt
1/60. |
IP
1/30. |
ICC/IF
1/50. |
WB
1/1000. Detects a band of approximately 23, 19 kDa (predicted molecular weight: 20, 14 kDa). |
靶标
-
功能
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. -
组织特异性
Expressed in mature B-cells, but not in T-cells or monocytes. -
疾病相关
Note=A chromosomal aberration involving TNFRSF17 is found in a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(4;16)(q26;p13) with IL2. -
序列相似性
Contains 1 TNFR-Cys repeat. -
细胞定位
Cell membrane. Endomembrane system. Perinuclear Golgi-like structures. - Information by UniProt
-
数据库链接
- Entrez Gene: 608 Human
- Omim: 109545 Human
- SwissProt: Q02223 Human
- Unigene: 2556 Human
-
别名
- B cell maturation antigen antibody
- B cell maturation factor antibody
- B cell maturation protein antibody
see all
图片
-
BCMA was immunoprecipitated from 0.35 mg of U266B1 (human multiple myeloma B lymphocyte cell line) whole cell lysate with ab253242 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab253242 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/1000 dilution.
Lane 1: U266B1 whole cell lysate 10 μg (Input).
Lane 2: ab253242 IP in U266B1 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab253242 in U266B1 whole cell lysate.Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds. -
Flow cytometric analysis of HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) (left) or U266B1 (human multiple myeloma B lymphocyte cell line) (right) cells labeling BCMA with ab253242 at 1/60 dilution (red) compared with Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077), at 1/2000 dilution was used as the secondary antibody.
Gated on viable cells.
Negative control: HEK-293T cells(PMID: 18025285.
-
All lanes : Anti-BCMA antibody [EPR22457-260] (ab253242) at 1/1000 dilution
Lane 1 : U266B1 (human multiple myeloma B lymphocyte cell line) whole cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 20, 14 kDa
Observed band size: 19 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking and dilution buffer: 5% NFDM/TBST.
BCMA is a glycoprotein.
The molecular weight observed is consistent with what has been described in the literature (PMID: 23776238, 10908663,
8527407)Negative control: HEK-293T (PMID: 18025285).
-
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U288B1 (human multiple myeloma B lymphocyte cell line) or HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) cells labeling BCMA with ab253242 at 1/50 dilution, followed by a Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).
Confocal image showing cytoplasmic and weak membranous staining in U266B1 cell line (PMID: 8527407) is observed.
Negative control: HEK-293T cells(PMID: 18025285).
The nuclear conter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) at 1/200 dilution (red).Secondary antibody only control: Used PBS instead of primary antibody, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
数据表及文件
-
SDS download
-
Datasheet download
Certificate of Compliance
文献 (2)
ab253242 被引用在 2 文献中.
- Liu Y et al. Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. Front Oncol 12:1037934 (2022). PubMed: 36353540
- Ndacayisaba LJ et al. Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci 23:N/A (2022). PubMed: 36362214